John Sullivan

Two Bear Capital thesis

Abilita Therapeutics Abilita Therapeutics enables discovery of novel therapeutics for previously undruggable membrane protein targets. Abilita Therapeutics enables discovery of novel therapeutics for previously undruggable membrane protein targets. About the company Abilita Therapeutics on LinkedIn Abilita Therapeutics website Abilita Therapeutics is a biotech company specializing in discovering and developing therapies for the most challenging membrane proteins, including GPCRs, ion channels and transporters. Despite their high significance, hundreds of such drug targets remain untapped. Abil

Sector and stage focus

• Seed: BioTech, Health IT, Digital Health, Health & Hospital Services
• Series A: Health IT, BioTech, Health & Hospital Services, Digital Health
• general: Boston / New England

Is John Sullivan a fit for your round?

Upload your pitch deck and see whether John Sullivan appears in your top 20 matches.